Your browser doesn't support javascript.
loading
Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients.
Machiels, Jean-Pascal; Gomez-Roca, Carlos; Michot, Jean-Marie; Zamarin, Dmitriy; Mitchell, Tara; Catala, Gaetan; Eberst, Lauriane; Jacob, Wolfgang; Jegg, Anna-Maria; Cannarile, Michael A; Watson, Carl; Babitzki, Galina; Korski, Konstanty; Klaman, Irina; Teixeira, Priscila; Hoves, Sabine; Ries, Carola; Meneses-Lorente, Georgina; Michielin, Francesca; Christen, Randolph; Rüttinger, Dominik; Weisser, Martin; Delord, Jean-Pierre; Cassier, Philippe.
Afiliação
  • Machiels JP; Medical Oncology, Cliniques Universitaires Saint-Luc, Brussels, Belgium jean-pascal.machiels@uclouvain.be.
  • Gomez-Roca C; UCLouvain, Brussels, Belgium.
  • Michot JM; Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
  • Zamarin D; Department of Innovative Therapies and Early Phase trials (DITEP), Gustave Roussy, Villejuif, France.
  • Mitchell T; Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
  • Catala G; Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Eberst L; Medial Oncology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
  • Jacob W; Department of Medicine, Centre Léon Bérard, Lyon, France.
  • Jegg AM; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.
  • Cannarile MA; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.
  • Watson C; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.
  • Babitzki G; A4P Ltd, Sandwich, UK.
  • Korski K; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.
  • Klaman I; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.
  • Teixeira P; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.
  • Hoves S; Pharma Research and Early Development, Roche Innovation Center Welwyn, Welwyn Garden City, UK.
  • Ries C; Roche Innovat Ctr Munich Oncol Discovery Pharma, Penzberg, Germany.
  • Meneses-Lorente G; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.
  • Michielin F; Pharma Research and Early Development, Roche Innovation Center Welwyn, Welwyn Garden City, UK.
  • Christen R; Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
  • Rüttinger D; Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
  • Weisser M; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.
  • Delord JP; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.
  • Cassier P; Department of Medicine, Centre Léon Bérard, Lyon, France.
J Immunother Cancer ; 8(2)2020 10.
Article em En | MEDLINE | ID: mdl-33097612
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Receptor de Fator Estimulador de Colônias de Macrófagos / Antígenos CD40 / Anticorpos Monoclonais Humanizados / Neoplasias Limite: Female / Humans / Male Idioma: En Revista: J Immunother Cancer Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Bélgica
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Receptor de Fator Estimulador de Colônias de Macrófagos / Antígenos CD40 / Anticorpos Monoclonais Humanizados / Neoplasias Limite: Female / Humans / Male Idioma: En Revista: J Immunother Cancer Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Bélgica